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ABSTRACT 1 
Following infusion of the anti-CD28 superagonist monoclonal antibody 2 
TGN1412, three of six previously healthy, young male recipients developed 3 
gastrointestinal irritability associated with increased expression of  4 
‘gut-homing’ integrin β7 on peripheral blood αβT-cells. This subset of patients 5 
with intestinal symptoms also displayed a striking and persistent expansion of 6 
putative Vδ2+ γδT-cells in the circulation which declined over a two-year period 7 
following drug infusion, concordant with subsiding gut symptoms. These data 8 
demonstrate that TGN1412-induced gastrointestinal symptoms were 9 
associated with dysregulation of the ‘gut-homing’ pool of blood αβ and γδT-10 
cells, induced directly by the antibody and/or arising from the subsequent 11 
cytokine storm.  12 
 13 
SIGNIFICANCE 14 
Following TGN1412-induced cytokine storm, 3 of 6 patients developed 15 
gastrointestinal irritability associated with expansion of gut-homing αβ and γδT-16 
cells. These findings may elucidate the pathology of immune-related adverse 17 
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Introduction 1 
In higher primates, the blood T-cell pool contains diverse αβT-cells and 2 
semi-invariant ‘unconventional’ T-cells that recognize either microbial peptides 3 
or metabolites, respectively (1). In both cases, antigen activation can stimulate 4 
these cells to upregulate the gut-homing integrin α4β7 and traffic to the intestine 5 
(2-4). Gut microbes, and the metabolic activities these perform, vary between 6 
host species. Consequently, the compounds generated and their conditioning 7 
effects on peripheral blood T-cell responses are likely to differ between mice 8 
and humans (5, 6). The influence of these microbial products may also diverge 9 
between individual recipients of agonist/antagonist immunotherapies; gut 10 
bacteria from patients with melanoma who respond to immune checkpoint 11 
blockade are enriched for anabolic functions proposed to stimulate host 12 
immunity (7). However, the extent to which peripheral blood T-cell responses 13 
contribute to these modulatory effects in vivo remains unclear.  14 
Some of the most common antigen-specific lymphocytes in human blood 15 
are gut-tropic T-cells specialized to detect various bacterial metabolites (1, 8). 16 
However, the frequencies and phenotypes adopted by these cells can differ 17 
between individuals and age groups (9, 10), and their impact on 18 
immunotherapeutic outcomes in treated patients is not well understood. It is 19 
now well-recognized that checkpoint inhibitors can be associated with immune-20 
related adverse events (irAEs) affecting the gut, most notably symptoms of 21 
diarrhea and colitis following blockade of cytotoxic T-lymphocyte antigen-4 22 
(CTLA-4) or programmed cell death 1 (PD-1) in patients with melanoma (7, 11). 23 
However, it is still unclear to what extent gastrointestinal irAEs are caused by 24 
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disruption of local mucosal immunoregulation, versus systemic drug effects on 1 
gut-homing lymphocytes (12).  2 
In March 2006, six healthy volunteers suffered from cytokine release 3 
syndrome (CRS) during a phase 1 first-in-man clinical trial of the monoclonal 4 
antibody TGN1412 (13). In pre-clinical studies, this anti-CD28 super-agonist 5 
induced preferential lymphocytosis of regulatory T-cells in the absence of 6 
systemic inflammation (14, 15); the immunological basis for antibody-induced 7 
CRS and resultant lymphopenia in the human trial has remained unclear.  8 
In addition to acute symptoms of CRS from which all six patients recovered 9 
(13), three patients suffered from prolonged gastrointestinal irritability of 10 
unknown etiology, suggesting unexpected TGN1412 antibody and/or CRS 11 
effects on gastrointestinal immunity. We therefore undertook a detailed 12 
investigation of peripheral blood distribution and expression levels of integrin 13 
β7 aiming to understand the immunological basis for these symptoms. These 14 
analyses revealed that blood αβT-cells from patients who suffered from gut 15 
irritability displayed significantly enhanced levels of β7 expression that were not 16 
observed in either asymptomatic patients or healthy controls. In addition, 17 
TGN1412-induced gut symptoms were associated with a striking expansion of 18 
circulating γδT-cells (putative phosphoantigen metabolite-responsive Vγ9Vδ2+ 19 
lineage) that was still evident two years after drug infusion. Together, these 20 
data suggest that in three of six recipients, the TGN1412 antibody or 21 
subsequent cytokine storm caused sustained dysregulation of the gut-homing 22 
T-cell pool, which gradually normalized over the two-year period following 23 
antibody infusion, concordant with subsiding gastrointestinal symptoms. 24 
25 
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METHODS 1 
Clinical trial 2 
Details of the first 30 days of clinical follow-up of the serious adverse event 3 
(SAE) have been reported previously. The patients presented herein 4 
correspond with those previously identified as follows (13): 1-B, 2-A, 3-F, 4-E, 5 
5-C, and 6-D. The TGN1412 antibody was produced by TeGenero AG 6 
(Wϋrzberg, Germany), manufactured by Boehringer Ingelheim (Germany), and 7 
the clinical trial was conducted by contract research organization PAREXEL 8 
International (Waltham, MA, USA) on leased premises at Northwick Park 9 
Hospital, London, UK. The authors of this report were not involved in either pre-10 
clinical or clinical testing of TGN1412.  11 
 12 
Patients and data sources 13 
Patients were clinically followed, off trial, and assessed as a cohort following 14 
the SAE (13). Based on clinical need and requirements for SAE follow-up, the 15 
lead clinician (NP) requested immunological monitoring, including analysis of 16 
peripheral blood T-cell subsets alongside intracellular and serum cytokine 17 
levels. Monitoring commenced 10 days after infusion of TGN1412 and the 18 
patients were evaluated at 21 time-points over the subsequent two years. All 19 
patient blood samples were anonymized and the scientists performing the 20 
immunological tests were not aware of patient symptoms, signs, or clinical 21 
laboratory data. Patients were assessed by the lead clinician at the same 22 
intervals wherein blood was procured for monitoring. Control blood samples 23 
from healthy male volunteers (n=24) were obtained in parallel with the patient 24 
samples after written informed consent. The six volunteers who received 25 
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TGN1412 were male and had a median age of 29.5 years (range 19-34) at the 1 
time of recruitment into the first-in-man trial. Healthy control volunteers were 2 
male and had a median age of 30 years (range 19-42). All patients were well 3 
during the two-week period preceding the clinical trial and were without 4 
significant medical history. Patients B and C were lost to immunological follow-5 
up after 15 and 22 months, respectively. Following development of 6 
gastrointestinal symptoms in three of the six patients, additional assessment of 7 
β7 integrin expression on peripheral blood T-cells was introduced for all patients 8 
at four separate time-points over the two-year follow-up. All clinical information 9 
was withheld from the scientists who performed these analyses (NEM, AJS, 10 
CLP, ERM, NLG, HOA, SCK) until laboratory investigations were complete. All 11 
six patients consented to immunological monitoring and have given written 12 
informed consent to the publication of data presented in this report. 13 
 14 
Immune monitoring 15 
Specific leukocyte subset monitoring began on Day+10 following TGN1412 16 
infusion and was repeated every three or four days for the first two weeks, then 17 
weekly for four weeks, then every four weeks for three months, then every six 18 
weeks for the remainder of eight months (time-points 1-17). In year two of 19 
monitoring, patients were evaluated every three months (time-points 18-21). In 20 
the first six months, whole blood was assessed for T-cell subsets, numbers, 21 
phenotypes and intracellular cytokine expression. After six months, the tests 22 
were rationalized to those that were most informative. Additional correlates of 23 
immune function included assessment of T-cell receptor Vβ repertoire (kit kindly 24 
donated by Beckman Coulter), and T-cell homing markers for the 25 
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gastrointestinal tract and skin based on expression of β7 integrin and 1 
cutaneous leukocyte antigen (CLA), respectively. The bulk of these data are 2 
presented elsewhere – this report focuses on the gut-homing subsets. These 3 
studies were conducted in a laboratory that operates under Good Laboratory 4 
Practice (GLP) principles, undertakes exploratory research and were 5 
performed using established laboratory protocols that were Minimal Information 6 
About T-cell Assays (MIATA) compliant (Supplementary MIATA information). 7 
The assays and reagents employed were previously validated and tested for 8 
assay performance during the course of standard general investigative 9 
research. 10 
 11 
Flow Cytometry 12 
Peripheral whole blood was obtained by venipuncture into sodium-heparin 13 
Vacutainer™ tubes (Becton-Dickinson) and then directly labeled with 14 
monoclonal antibody (mAb; Supplementary Table 1) for 15min at room 15 
temperature. After mAb labeling, Optilyse C reagent (Immunotech, Marseilles) 16 
was used to lyse erythrocytes for 15min before washing the cells twice in cold 17 
FACS buffer (2% FCS, 0.02% sodium azide, and 1mM EDTA in PBS) for 5min 18 
at 300G. Cell pellets were fixed in 0.4mL paraformaldehyde (1%) and stored at 19 
4oC in the dark until acquired on a FACSCalibur flow cytometer using CellQuest 20 
software (Becton-Dickinson). All analyses were performed using WinList 21 
software (Verity Software House, Maine, USA). Absolute cell counts were 22 
determined using Flow-Count™ Fluorospheres (Beckman Coulter) added to 23 
the cells immediately prior to acquisition. 24 
 Viable cells were gated according to their characteristic light-scatter 25 
properties, and individual leukocyte subsets identified based on expression of 26 
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subset-specific surface antigens. Major CD3+ T-cell subsets were identified 1 
based on differential expression of CD8 (CD8+ T-cells were CD3+/CD8+ and 2 
putative CD4+ T-cells were CD3+/CD8-), since CD8 is less susceptible than CD4 3 
to down-regulation during T-cell stimulation used in the intracellular cytokine 4 
determination protocol. In each subset, naïve and memory populations were 5 
enumerated by further double staining; naïve cells were CD45RA+/CD45RO- 6 
and memory cells were CD45RA-/CD45RO+. Expression of CD69 in CD4+ and 7 
CD8+ T-cell subsets was used to identify activated T-cells. 8 
 9 
Intracellular cytokine staining 10 
Peripheral whole blood cells were cultured in complete medium (Dutch-11 
modified RPMI-1640 medium, 10% FCS, 20mM L-glutamine, 100u/mL 12 
penicillin, 100μg/mL streptomycin) with or without monensin (3μM), PMA 13 
(10ng/mL), and ionomycin (2μM) for 4h at 37oC, 5%CO2. Cells were then 14 
surface-labeled with anti-CD3 and anti-CD8 mAb for 15min at room 15 
temperature. Optilyse C reagent (Immunotech, Marseilles) was used for lysis 16 
of erythrocytes (0.5mL per 100μL aliquot of blood) and the samples were 17 
incubated for 15min at room temperature. The remaining cells were twice 18 
washed in cold FACS buffer for 5min at 300G, re-suspended in 100μL 19 
Leucoperm A (Serotec, Oxford), and then incubated for 15min at room 20 
temperature. The partially fixed cells were next washed twice in FACS buffer 21 
and re-suspended in 100μL Leucoperm B (Serotec, Oxford). For intracellular 22 
staining, the cells were labeled with 5μL anti-cytokine mAb for 30min on ice 23 
then washed twice in FACS buffer and fixed in 0.4mL paraformaldehyde (1%) 24 
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prior to storage in the dark at 4oC (acquisition by flow-cytometry was performed 1 
within 24 hours). 2 
 3 
Statistics 4 
Statistical analyses were conducted using SigmaStat™3.5 or SigmaPlot™11.0 5 
software (Systat Software UK Ltd, London). The TCR-V repertoire data were 6 
compared using Kruskal-Wallis One-Way Analysis of Variance on Ranks. One-7 
Way Analysis of Variance with All-Pairwise Multiple Comparison Procedures 8 
(Holm-Sidak method) was used to compare β7 integrin expression over time 9 
between patient subsets and 10 healthy controls. Differences in expression of 10 
γδ-TCR between patients and controls were evaluated by Student’s t-test. 11 
 12 
13 
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RESULTS 1 
Three of six patients (A, B and E) who received TGN1412 suffered from 2 
gastrointestinal symptoms (Common Terminology Criteria for Adverse Events 3 
grade 1-2 irAE), manifesting as loose and frequent bowel motions or diarrhea 4 
(primarily after consuming spicy foods; hereafter described as ’gut irritability’), 5 
not present prior to drug exposure. These symptoms started within one month 6 
of TGN1412 infusion and subsequently decreased in intensity over the two-year 7 
follow-up period. Symptoms persisted in patients B and E at two years. Patient 8 
B displayed the most pronounced gut symptoms and in the first year of follow-9 
up underwent a full gastrointestinal work-up including duodenal biopsies (which 10 
were normal), and removal of a colonic polyp which exhibited non-specific 11 
inflammation.  12 
 13 
Gut irritability in TGN1412 recipients was associated with increased β7 14 
expression by circulating αβT-cells  15 
Integrin α4β7 binding to MAdCAM-1 facilitates leukocyte recruitment into 16 
intestinal tissues (16). Accordingly, T-cell expression of α4β7 is significantly 17 
modulated during active gut inflammation, and inhibition of the α4β7:MAdCAM-18 
1 axis has been an effective therapeutic strategy in patients with inflammatory 19 
bowel disease (IBD) (17, 18). Development of gut symptoms in three of the six 20 
TGN1412 recipients prompted us to assess T-cell expression of β7 integrin at 21 
four separate time-points over the two-year follow-up period. CD45RA+ 22 
(predominately naïve) T-cells in the blood of both patients and healthy controls 23 
uniformly expressed an intermediate level of β7, whereas CD45RA- (antigen-24 
experienced effector/memory) T-cells included both β7+ and β7- subsets, 25 
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representing putative gut-homing and non-intestinal populations, respectively 1 
(Fig. 1a). In healthy volunteers, memory T-cells were evenly distributed 2 
between β7+ and β7- subsets (median ratio 0.98, interquartile range 0.80-1.19; 3 
Fig. 1b). Patients C, D, and F, who did not exhibit gastrointestinal symptoms, 4 
were indistinguishable from control subjects at all time points analyzed. In 5 
contrast, patients with gut irritability (A, B, and E) displayed increased β7+ 6 
memory T-cells at 8.6 months (p<0.001) and 10.2 months (p=0.003) post-7 
TGN1412 infusion (Fig. 1b). At 8.6 months, both CD45RA+ and CD45RA- T-8 
cells from patients A, B, and E also exhibited higher levels of β7 integrin 9 
expression per cell (mean fluorescence) compared with T-cells from healthy 10 
controls, although this had normalized by one year post-infusion 11 
(Supplementary Fig. 1a and b). Sustained changes in both CD8+ and CD8- 12 
(presumed CD4+) memory T-cells contributed to the elevated β7 expression 13 
detected in patients with gut irritability (Supplementary Fig. 1c and d). Fewer 14 
than 8% of β7+ memory T-cells from either patients or controls expressed 15 
CD103/E integrin, the alternative binding partner for β7 (Fig. 1c), consistent 16 
with reports that β7 primarily forms complexes with the α4 subunit on blood T-17 
cells (16), and confirming that the data presented here reflected changes in the 18 
patients’ α4β7+ compartment. Together, these findings indicated that gut 19 
irritability in three of six patients infused with TGN1412 was associated with a 20 
sustained increase in gut-homing potential among both naïve and memory αβT-21 
cells. 22 
  23 
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TGN1412-induced gut irritability correlated with peripheral blood 1 
expansion of putative Vδ2+ γδT-cells 2 
In addition to the features outlined above, the blood of patients who developed 3 
gut irritability after TGN1412 infusion contained a distinct subset of CD3hi T-4 
cells that was not present in the circulation of either asymptomatic patients or 5 
healthy controls (Fig. 2a). These cells displayed a CD4-CD8- ‘double negative’ 6 
phenotype characteristic of unconventional lymphocytes (data not shown) and 7 
expressed uniformly high levels of CD45RO (Fig. 2b) and β7 integrin (Fig. 2e), 8 
but lacked CD103 (Fig. 2f) and did not express any of the common Vβ-TCR 9 
repertoire variants assayed at 8.6 and 12.1 months following TGN1412 infusion 10 
(Supplementary Fig. 2). These features strongly implicated an expansion of 11 
‘unconventional’ Vγ9Vδ2+T-cells (hereafter Vδ2+T-cells) which express high 12 
levels of α4β7 in human blood (3, 19) and are rapidly recruited to mucosal 13 
tissues in higher primates in vivo (20, 21). Further support for this lineage 14 
identity was later provided by the absence of αβ-TCR (Fig. 2g) and lack of 15 
markers for natural killer cells (CD56) or invariant natural killer T-cells (antibody 16 
6B11; data not shown), but high expression levels of γδ-TCR (22) (Fig. 2h) as 17 
well as NKG2D, and CD161 (23, 24) (data not shown).  18 
Analysis at 15 months post-infusion confirmed that typical low numbers 19 
of γδT-cells were present in peripheral blood from unaffected patients C, D, and 20 
F, as well as in six healthy controls analyzed in tandem, but these cells were 21 
not CD3hi (data not shown). In contrast, total γδT-cells (including both CD3+ and 22 
CD3hi subsets) remained significantly increased in patients with gut irritability 23 
(A, B, E; 7.92-8.59%) compared with healthy controls (2.5-6.5%; p=0.002) even 24 
at this late time point (more than one year post-infusion). In the blood of patients 25 
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A, B, and E, the γδT-cell pool reached peak numbers (16% of total T-1 
lymphocytes) approximately 1.5 months post-TGN1412 exposure, followed by 2 
a gradual decline coincident with improvement in gastrointestinal symptoms 3 
(Fig. 2i and j). Up to 25% of these γδT-cells displayed an activated/CD69+ 4 
phenotype, and expression of this marker decreased steadily over the following 5 
seven months (Fig. 2k). No other clinical or laboratory features correlated with 6 
γδT-cell expansion as observed in the three symptomatic patients. Importantly, 7 
expansion of gut-homing lymphocytes in the patients with gut irritability was not 8 
restricted to γδT-cells alone, because higher numbers of β7+T-cells were still 9 
detected in these individuals (Fig. 1) when the γδT-cell (CD3hi) population was 10 
excluded from this analysis (Supplementary Fig. 3). 11 
The IFNγ-producing subset of blood Vδ2+T-cells declines naturally with 12 
age and is lost more rapidly in men after the age of 30 (25), with both ethnic 13 
and environmental variables further impacting on the dynamics of this 14 
compartment (26). To determine whether the expanded γδT-cells detected in 15 
TGN1412 recipients remained functionally competent, and also to understand 16 
how these cells might be contributing to gastrointestinal irritability, we next 17 
assessed cytokine expression using a standard intracellular staining approach. 18 
The γδT-cell population produced low-levels of IL-10 in vitro in the absence of 19 
exogenous stimulation (Fig. 3), but did not appear to spontaneously produce 20 
either IFNγ or IL-4. However, γδT-cell reactivation with phorbol myristate 21 
acetate and ionomycin resulted in substantial production of IFNγ across a wide 22 
range of time points analyzed, starting from one month post-infusion, when 23 
symptoms of gut-irritability were first identified. Together, these data suggest 24 
that development of intestinal symptoms in patients infused with TGN1412 was 25 
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associated with sustained expansion of circulating Vδ2+T-cells with IFNγ-1 
producing capacity, as well as increased gut-homing potential within the blood 2 
αβT-cell pool. 3 
4 
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DISCUSSION 1 
This report provides unique evidence that TGN1412 antibody, or the 2 
subsequent CRS, dysregulated intestinal immunity in three of six drug 3 
recipients, outside of an identified infectious etiology; gut irritability was 4 
associated with sustained enhancement of mucosal trafficking in both 5 
conventional and unconventional T-cell subsets.  6 
While the immunological response to TGN1412 infusion was surprisingly 7 
uniform in many respects (13), the long-term impact of the drug on mucosal 8 
immunity varied markedly between patients. Typical populations of β7+αβT-9 
cells (16) were present as expected in all trial patients, but enhanced β7 10 
expression levels and the surprising expansion of γδT-cells were unique to 11 
patients with symptoms of gut irritability. This variability of response may reflect 12 
patient-specific differences in homeostatic T-cell reconstitution after TGN1412-13 
induced lymphopenia (13) and/or differential γδT-cell responses to high levels 14 
of cytokines such as TNFα (27) following infusion of TGN1412. The peripheral 15 
blood location, kinetics, magnitude, and duration of these γδT-cell expansions, 16 
together with uniform expression of CD45RO (28) and high surface levels of 17 
β7, strongly implicate the Vγ9Vδ2+T-cell lineage which responds to non-peptide 18 
‘phosphoantigens’ (pAg) derived from microbes and stressed/transformed host 19 
cells (29, 30). Vγ9Vδ2+ T-cells undergo rapid polyclonal expansion in the first 20 
few weeks of human life, likely driven by pAg-producing bacteria within the gut 21 
microbiome; thereafter, the repertoire displays progressive selection of shared 22 
or ‘public’ pAg-reactive clones (defined by characteristic Vγ9JP and Vδ2 23 
chains) (31). With advancing age, the Vδ2+T-cell compartment becomes 24 
increasingly oligoclonal, but different individuals may still display diverse or 25 
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‘private’ Vγ9Vδ2+ clonal expansions with distinct effector phenotypes (32), 1 
potentially including variable expression of gut-homing markers. It is therefore 2 
possible that the TGN1412 recipients with gut symptoms (A, B, and E) featured 3 
Vδ2+ clonotypes that were absent from the blood of those without (C, D and F). 4 
These cells may have exhibited different thresholds for pAg activation and 5 
intestinal recruitment in the context of cytokine storm. Rapid expansion of 6 
Vγ9JP+ γδT-cells has also been observed during immune reconstitution of 7 
patients undergoing allogeneic hematopoietic stem cell transplantation, but the 8 
clonotypes generated following donor cell infusion were substantially different 9 
from those present either in the donor or the recipient pre-transplant (33). 10 
Indeed, while Vδ2+T-cells constitute only a minor fraction of total circulating 11 
lymphocytes in healthy individuals, their number and activation state in 12 
peripheral blood and body tissues has been correlated with therapeutic and 13 
clinical outcomes (34-36). Work from our own laboratory has also demonstrated 14 
that activated blood Vδ2+T-cells rapidly up-regulate β7 and can populate 15 
human gut lamina propria where they induce substantial mucosal production of 16 
IFNγ (3). In patients with Crohn’s disease, gut-homing potential and pro-17 
inflammatory properties of Vδ2+T-cells are enhanced (36), suggesting that they 18 
play a key role in human gut immunity and inflammation. In future, the 19 
microbiome composition of pAg-producing bacteria and blood γδT-cell 20 
repertoire may also prove to be important determinants of clinical outcome in 21 
patients undergoing immunotherapy. 22 
The Vδ2+ lineage is absent in rodents and does not recognize antigen in 23 
the context of MHC (37). Instead, Vδ2+T-cells respond to butyrophilin (BTN) 24 
proteins, considered as part of the B7 family of costimulatory receptors (37), 25 
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with critical roles recently identified for both BTN3A1 and BTN2A1 (38). Vδ2+T-1 
cells lack alloreactivity while displaying potent anti-tumor and anti-microbial 2 
functions, such that reconstitution of this lineage after chemotherapy-induced 3 
lymphopenia may reduce infection rates in patients receiving hematopoietic 4 
stem cell transplantation, without increased incidence of graft versus host-5 
disease (33, 39). Expansion of blood Vδ2+T-cells has been observed in CRS, 6 
most notably in healthcare workers exposed to SARS-CoV-1 in the 2003 7 
outbreak; these individuals displayed strikingly similar features including 8 
relatively stable αβT-cell numbers and TCR-Vβ repertoire, whereas marked 9 
expansions of Vδ2+T-cells with IFNγ-producing capacity were still evident three 10 
months after disease onset (40). These findings resemble data from nonhuman 11 
primate models in which pAg injection stimulates blood Vδ2+T-cell expansion 12 
in vivo (41), leading to accumulation of an IFNγ-producing subset both in lungs 13 
and intestinal mucosa (20), accompanied by robust Th1 immune protection 14 
against a range of different pathogens.  15 
Vδ2+T-cells undergo expansion in response to a variety of microbial 16 
infections and can dominate the blood lymphocyte pool for extended periods 17 
(10). It is also now widely recognized that Vδ2+T-cells display tissue-tropic 18 
phenotypes consistent with trafficking to barrier sites where pAg-producing 19 
microbes and tumors frequently originate (29, 30). In particular, Vδ2+T-cells are 20 
associated with effective host immunity to pAg-producing mycobacteria and 21 
robust responses to bacillus Calmette-Guérin (BCG) vaccination (42, 43), 22 
which induces population expansion and upregulation of CD69 and IFNγ 23 
expression in vitro. Notably, these responses are enhanced in BCG-responders 24 
compared with non-sensitized controls (44, 45), and the pool of Vδ2+T-cells 25 
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generated lacks lymph node homing receptors while displaying homogenous 1 
expression of CD28 (45). Therefore, TGN1412 may have directly stimulated 2 
Vδ2+T-cells in the trial patients, and prior microbial exposures such as BCG 3 
may have influenced subsequent responses to mucosal pathogens and/or 4 
cytokine storm (as also postulated in the context of COVID-19 (46)). Indeed, 5 
while previous studies have primarily linked Vδ2+T-cell expansion with host 6 
protection against bacterial pathogens, these lymphocytes can also lyse 7 
stressed host cells infected with viruses including influenza (47) and SARS-8 
CoV-1 (40). Together, these data suggest that monitoring of gut-homing αβ and 9 
γδT-cell populations is likely to shed important new light on the initiation, 10 
propagation, monitoring, and resolution of mucosal symptoms in human 11 
subjects with irAEs or suffering CRS as a result of immunotherapy or severe 12 
infections such as COVID-19. 13 
14 
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FIGURE LEGENDS 1 
 2 
Fig. 1 Blood T-cell expression of β7 integrin and CD103 following 3 
TGN1412-induced cytokine storm. CD3+ T-cells were identified in whole 4 
blood and β7 expression on memory (CD45RA-) and naïve (CD45RA+) subsets 5 
was assessed. (a) Representative data for a healthy control and two patients 6 
are shown, one in whom β7+ cells were prominent in the memory T-cell 7 
population (patient B) and one in whom β7+ memory T-cells appeared normal 8 
(patient C). Staining with isotype-matched control antibodies was contained 9 
within the boxed region in the lower left of the plots. (b) Summary data for 10 
memory T-cells showing the ratio of β7+:β7- cells assessed at four separate 11 
time-points over a period of seven months. In patients with gut irritability (A, B, 12 
and E), the ratio of β7+:β7- cells was significantly higher at 8.6 and 10.2 months 13 
than was observed in healthy controls. (c) Proportion of β7+ memory T-cells 14 
expressing CD103 in the patients, assessed over four separate time-points. 15 
Patient B, the most symptomatic, displayed the highest ratio of β7+:β7- memory 16 
T-cells and lowest percentage of CD103+ cells, suggesting a selective 17 
expansion of α4β7+ ‘gut-homing’ memory T-cells. Data for Patient D were not 18 
available at time points 10.2 and 12.1 months, nor for patient A at 12.1 months. 19 
Fig. 2 Prolonged expansion of circulating γδT-cells (putative Vδ2+) in 20 
patients with gut irritability after TGN1412-induced cytokine storm. 21 
Peripheral blood CD3+ T-cells (a – R1) included a CD3hi subset (black 22 
histogram; identified by γδTCR-specific mAb used in 2h) which exhibited a 23 
CD4-CD8- ‘double negative’ phenotype characteristic of unconventional 24 
lymphocytes (data not shown). This discrete population uniformly expressed 25 
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CD45RO and was clearly identifiable in the blood of patients A, B, and E (b – 1 
R2; representative example from patient A), but not in patient C, D, or F (c – 2 
R2; representative example from patient C), or in 24 healthy controls analysed 3 
in parallel (d – R2; representative example). Example analyses in (b), (c) and 4 
(d) are taken from 10 days post-TGN1412 infusion. CD3hiT-cells in the patients 5 
with gut symptoms uniformly expressed 7 but not CD103/E (e and f) 6 
indicating that these cells displayed the 47 heterodimer which mediates 7 
homing to the intestine (representative example from patient B). Staining with 8 
a specific mAb confirmed that the CD3hi cells were -TCR- (g – R3) but 9 
strongly expressed γδ-TCR (h; black histogram - unfilled trace indicates isotype 10 
control) and mapped to the CD3hi population observed previously (a – R1; black 11 
histogram). While total T-cell numbers in the patients were comparable at early 12 
time points (i) the CD3hi γδT-cells subset was present only in patients A, B, and 13 
E, and persisted for up to two years post-TGN1412 infusion, decreasing slowly 14 
over time (j). In patient E, symptoms of gut irritability and diarrhea worsened at 15 
month 21, accompanied by an increase in CD3hi γδT-cells at month 24 at which 16 
time symptoms had improved and he had more formed stool (although still not 17 
normal). Peak population size of CD3hi γδT-cells (16% of the total T-lymphocyte 18 
pool) was reached approximately 1.5 months post-TGN1412 exposure. 19 
Between 5-25% of this population displayed an activated (CD69+) phenotype 20 
that decreased steadily over seven months (k). The median values and inter-21 
quartile ranges of data obtained from healthy subjects (n = 24) are provided for 22 
reference (horizontal dashed lines). 23 
Fig. 3 The expanded γδT-cell population spontaneously produced IL-10 24 
and expressed IFNγ upon reactivation. To assess the functional potential of 25 
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CD3hiβ7+γδT-cells, whole blood cells were cultured with or without monensin 1 
and exogenous stimuli (PMA and ionomycin) for four hours prior to surface 2 
labelling and intracellular staining with anti-cytokine monoclonal antibodies for 3 
analysis by flow-cytometry. CD3hiCD45RO+γδT-cells spontaneously produced 4 
low levels of IL-10 in the absence of exogenous stimulation. By 1.5 months 5 
post-TGN1412 infusion, a substantial proportion of CD3hiγδT-cells produced 6 
IFNγ upon reactivation with PMA and ionomycin. Dotted lines represent median 7 
and interquartile range of values obtained from conventional CD4+ αβT-cells in 8 
all patients (no CD3hi cells were identifiable in healthy volunteers to serve as 9 
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Supplementary Fig. 1 Enhanced integrin 7 expression levels on blood  
T-cells from patients with gut irritability. The level of7 expression, 
measured as mean fluorescence intensity (MFI) of 7-expressing cells, was 
determined on CD45RA- memory T-cells (a) and on CD45RA+ naïve T-cells (b). 
The level of7 was increased on both memory and naïve T-cells from patients 
with gut symptoms at 8.6 months post-infusion. Levels of 7 on cells from 
patients with gut irritability (A, B, and E) remained elevated at 10.2 months 
following drug administration in the case of naïve T-cells (b). However, 7 levels 
on patient T-cells were indistinguishable from those on T-cells from healthy 
controls by one year post infusion. The ratio of 7+:7- expression was also 
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determined separately for CD8+ (c) and CD8- (putative CD4+) (d) memory T-
cell populations. Changes in both CD8+ and putative CD4+ memory T-cells 
contributed to the enhanced expression of 7 in the affected patients. There 
was evidence of heterogeneity among the patients with gut symptoms; patient 
B, who developed the most pronounced and sustained gut symptoms, 
displayed enhanced 7 expression in both CD8+ and CD8- populations which 
normalised by 15 months, but such changes were confined to CD8+ T-cells only 
in patient A.  
  




Supplementary Fig. 2 CD3hi T-cells do not express common Vβ segments. 
CD3+ T-cells in peripheral blood were labelled with monoclonal antibodies 
against 24 common Vβ segments to assess the TCR repertoire of the CD3hi 
cells. T-cell Vβ repertoire was assessed at both (a) 8.6 months and (b) 12.1 
months post-TGN1412 infusion. (c) The distribution of V segments among 
patient T-cells was indistinguishable from the profile of six healthy age-matched 
volunteers analysed in parallel (p=0.856). In contrast, only ~5%  of CD3hi cells 
expressed any detectable V segment, suggesting that these might be 
oligoclonal cells expressing uncommon V chains, or alternatively represented 
a non- lineage (d; a representative example from patient A is shown at 12.1 
months post-TGN1412 infusion). Error bars indicate standard error of V 
segment expression.   




Supplementary Fig. 3 Expansion of CD3hiγδT-cells does not account for 
increased 7 expression observed among total CD3+ T-cells from patients 
with gut symptoms. When CD3hiT-cells were excluded from the analysis of 
CD45RA- memory T-cells (a), increased skewing towards 7 expression was 
still observed (b).  
 
 
